AARTI DRUGS LTD. - 524348 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclose herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2020 received from Link Intime India Private Limited, Registrar and Share Transfer Agent of our Company. AARTI DRUGS LTD. - 524348 - Board Meeting Intimation for Audited Financial Results For The Quarter Ended June 30, 2020.
AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/07/2020 ,inter alia, to consider and approve Audited Financial Results for the Quarter ended June 30, 2020. Aarti Drugs to Tata Comm: Earnings rise for 15 firms in Covid-19 economy
These companies reported an increase in revenue and/or profit before tax for the March quarter AARTI DRUGS LTD. - 524348 - Revised Disclosure Of Impact Of COVID-19 Pandemic Pursuant To SEBI Circular No.SEBI/HO/CFD/CMD1/CIR/P/2020/84 Dated May 20, 2020
With reference to discrepancy mail received from NSE dated July 8, 2020 and in line with above mentioned SEBI circular we are submitting herewith revised disclosure with reference to the impact of COVID-19 pandemic on various aspects of the business activities of the Company as below; AARTI DRUGS LTD. - 524348 - Shareholding for the Period Ended June 30, 2020
Aarti Drugs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2020. For more details, kindly Click here AARTI DRUGS LTD. - 524348 - Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 1010 Name of the Signatory :- RUSHIKESH DEOLEDesignation :- Company Secretary and Compliance Officer AARTI DRUGS LTD. - 524348 - Disclosure Of Impact Of COVID-19 Pandemic
With reference to SEBI Circular No.SEBI/HO/CFD/CMD1/CIR/P/2020/84 dated May 20, 2020 we would like to share an update with reference to the impact of COVID-19 pandemic on various aspects of the business activities of the Company. AARTI DRUGS LTD. - 524348 - Closure of Trading Window
This is to inform that the Trading Window of the Company will remain closed from Wednesday, July 1, 2020 until the expiry of 48 hours after the declaration of financial results of the Company for the quarter ended June 30, 2020. AARTI DRUGS LTD. - 524348 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the FY ended March 31, 2020. Aarti Drugs hits fresh all-time high; stock zooms 165% in 3 months
According to analysts at Centrum Broking, the launch of new products would improve the company's margins in the coming quarters